Clinical Trial: CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia

U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT06892951) titled 'CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia' on Jan. 18, 2024.

Brief Summary: To assess the efficacy of administrating daily caspofungin aerosols versus placebo for seven days, in adjunction of conventional systemic antifungal therapy during curative treatment of Pneumocystis pneumonia, on the clinical outcome at the end of the nebulized therapy, in order to support a "GO / NO GO" decision towards a phase III trial of nebulized caspofungin in those patients.

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Pneumocystis Pneumonia Pneumocystis Jirove...